PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)
Globenewswire·2025-08-26 12:00
Company advancing U.S. commercialization with FDA-approved ketamine and rare disorder NDA filingsTORONTO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a corporate update highlighting commercial readiness for ketamine (KETARx™) and an ambitious regulatory program aimed at advancing KETARx™ for rare disorders. Fabio Ch ...